Skip to main content

Table 1 Demographics and baseline characteristics (ITT population)

From: Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study

 EVO 2.5 mg (N = 35)EVO 5 mg (N = 36)EVO 10 mg (N = 36)SITA 100 mg (N = 39)
Gender, n (%)
 Female16 (45.7)19 (52.8)19 (52.8)18 (46.2)
Age, years
 Mean (SD)50.46 (9.33)53.17 (11.50)50.11 (9.36)52.10 (10.41)
BMI, kg/m2
 Mean (SD)29.79 (5.04)30.56 (4.18)29.80 (4.71)30.50 (4.76)
 Median29.331.129.630.6
 Min–max20.8–39.922.3–39.621.4–39.920.9–39.7
T2DM duration, yearsa
 Mean (SD)2.49 (4.03)1.12 (2.86)2.21 (4.42)1.18 (2.26)
 Median0.60.00.10.2
 Min–max0.0–18.00.0–13.60.0–21.00.0–11.0
HbA1c, %
 Mean (SD)9.09 (0.99)8.84 (0.85)8.95 (0.93)8.90 (0.94)
 Median9.28.89.09.0
 Min–max7.5–10.57.5–10.57.5–10.57.5–10.5
FPG, mg/dL
 Mean (SD)168.20 (48.56)182.19 (42.96)188.25 (50.12)193.10 (56.21)
 Median160.0172.0185.0183.0
 Min–max62.0–293.0109.0–301.0122.0–336.0104.0–342.0
  1. BMI body mass index, EVO evogliptin, FPG fasting plasma glucose, HbA1c glycated haemoglobin, ITT intention-to-treat, Max maximum, Min minimum, SD standard deviation, SITA sitagliptin, T2DM type 2 diabetes mellitus
  2. aCalculated as the number of years between the diagnosis of T2DM and signature of the informed consent